BLAINJECTIONINJECTABLE
Approved
Mar 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
ILUMYA (tildrakizumab-asmn) by Sun Pharmaceutical Industries Limited is interleukin-23 antagonists [moa]. First approved in 2018.
Drug data last refreshed 49m ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ILUMYA (tildrakizumab-asmn) is a monoclonal antibody that selectively targets interleukin-23 (IL-23), a key cytokine in inflammatory skin diseases. It is administered via subcutaneous injection and is indicated for plaque psoriasis and other IL-23-driven dermatologic conditions. The drug works by blocking IL-23 signaling, thereby reducing the inflammatory cascade that drives psoriatic plaques.
$32MPart D
PeakStable
At peak lifecycle with $32M Part D spending but modest claim volume (1,822 claims in 2023), suggesting high price per patient and stable but not expanding market penetration.
Mechanism of Action
Interleukin-23 Antagonists
Pharmacologic Class:
Interleukin-23 Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ILUMYA sits at peak lifecycle with stable but modest commercial performance, offering career opportunities primarily in defensive brand management, market access navigation, and field engagement rather than launch or expansion roles. Positions on the ILUMYA team typically focus on maintaining market share, managing reimbursement complexity (high price, modest volume), and competing against stronger entrants in the IL-23 space.
Brand Manager
Worked on ILUMYA at Sun Pharmaceutical Industries Limited? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.